eisai listed as a global 100 most sustainable corporation for the eighth time
highest ranked global pharmaceutical company
开元体育·(中国)官方网站 copyright(c) 2011 eisai china lnc.all rights reserved.
customer service hotline
021-62881220
about admin
this author has yet to write their bio.
meanwhile lets just say that we are proud admin contributed a whooping 62 entries.
entries by
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has submitted a marketing authorization application in japan for its in-house discovered fibroblast growth factor (fgf) receptor (fgfr1, fgfr2, fgfr3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: e7090, “tasurgratinib”) for biliary tract cancer with fgfr2 gene fusion. in japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with fgfr2 gene fusion by the ministry of health, labour and welfare, (mhlw). under this system, this application will be subject to priority review.
“leqembi® intravenous infusion” (lecanemab) for the treatment of alzheimer’s disease to be launched in japan on december 20
tokyo and cambridge, mass., december 13, 2023 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (aβ) monoclonal antibody “leqembi® intravenous infusion” (200 mg, 500mg, lecanemab) will be launched in japan on december 20, following its scheduled inclusion in the price listing on the japan national health insurance (nhi) drug price list.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: kyle tattle, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) announced today that eisai has submitted an application in japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, lenvima® (generic name: lenvatinib mesylate), in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s keytruda® (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (rcc). this is the first application to be submitted in japan for this combination therapy.
kyorin pharmaceutical co., ltd. (headquarters: chiyoda-ku, tokyo, president and ceo: shigeru ogihara, “kyorin”), a subsidiary of kyorin holdings, inc. (headquarters: chiyoda-ku, tokyo, president and ceo: yutaka ogihara), and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, “eisai”) have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four asean (association of southeast asian nations) member states; thailand, the philippines, malaysia and brunei. based on this agreement, eisai will acquire exclusive development and marketing rights from kyorin for the agent in the said four countries, and will be responsible for submitting a new drug application for the agent.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the european medicines agency (ema) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: lenvima® / kisplyx®, “lenvatinib”), in combination with anti-pd-1 therapy pembrolizumab (brand name: keytruda®), developed by merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) as a treatment f or patients with advanced renal cell carcinoma (rcc) and advanced endometrial carcinoma (ec), respectively.
eisai china policy on submission of ideas: 1. eisai china holdings ltd., its affiliates and subsidiaries (collectively, ” eisai china”) are committed to protecting the privacy of the information collected from external individuals and organizations through eisai china online opportunity submission process. information here refers to personal identifiable information and other personal data, as well […]
eisai china holdings ltd. / eisai china inc. shanghai branch address: 39-40th floor, park place, no.1601 nanjing xi road, shanghai, p.r.c tel: 021–24192888 fax: 021–24192891 zip code: 200040 suzhou factory address: 168# xingpu road,suzhou industrial park,jiangsu province p.r.c tel: 86-512-69566776 fax: 86-512-62576776 zip code: 215126 beijing branch address: 2303-2306 room, 23th floor, sk building, no.a 6 jianguomenwai […]
accessibility features of the site
eisai china is committed to making this website accessible to the broadest possible audience, regardless of technology or physical capability. to this end, we are working constantly to improve the overall usability of the site, using many of the existing international standards for accessibility on the internet as guidelines. images: • […]